Placeholder Banner

BIO Joins Diverse Coalition Promoting Market-Based Solutions to Address Prescription Drug Costs, Increase Patient Access and Choice

May 17, 2017

Washington, DC (May 17, 2017) – Today, the Biotechnology Innovation Organization (BIO) joins with a diverse coalition of stakeholders in endorsing a set of pro-competition, free-market-oriented solutions to lower healthcare costs while increasing patient access and choice to the medicines they need. The proposals, “Prescriptions for Competition, Value and Innovation,” were released by the Council for Affordable Health Coverage (CAHC), of which BIO is a member. The CAHC is a diverse coalition of healthcare stakeholders, including patient and consumer advocacy groups, employers, insurers, pharmacy benefit managers, and biopharmaceutical companies.

The proposed solutions focus on five different areas:

  • Increasing Competition: Bringing more generic and branded drugs to the market will increase competition, driving down costs and improving patient and provider choice.
  • Rewarding Value: Reward improved health outcomes and help to lower costs by reforming legal and regulatory barriers that impede private sector value-based contracting for prescription drugs based on outcomes in care.
  • Improving Data Infrastructure and Use: Improving data infrastructure and utilization will increase transparency and improve quality of care, while lowering costs and allowing for more widespread and efficient value and outcomes-based reimbursement contracts.
  • Empowering Consumers: Providing consumers with relevant, easily understood information about their drug choices, including information on their cost-sharing obligations.
  • Preserving What Works: Reject proposals that would undermine functioning markets and the thriving biopharmaceutical innovation ecosystem, or jeopardize patient access or safety.

Last year, BIO released a set of Principles on the Value of Biopharmaceuticals, the first-ever systemic, industry-endorsed set of commitments by research-based biopharmaceutical companies to support comprehensive and sustainable solutions to improve patient access to and affordability of innovative medicines,” said BIO President and CEO Jim Greenwood. “Today’s policy recommendations demonstrate that our industry is serious about following through on our commitment to engage with a broad range of stakeholders to identify and advocate for sound reforms that will improve the ability of patients to obtain and afford the innovative medicines they need – now and in the future.”

“BIO is proud to join this diverse coalition of patients, insurers, PBMs, and employers in endorsing common-sense, free-market policies to lower drug costs and increase patient access and choice,” Greenwood added.  “We look forward to working with the Administration and Congress and our coalition allies to secure implementation of these reforms as expeditiously as possible.”

The full set of proposals may be found at the Council for Affordable Health Coverage’s website:

Discover More
New Season of I am BIO Podcast to Showcase  Life-Changing Biotech Breakthroughs Launching February 27, spring 2024 season explores a new CRISPR therapy, advances in microbiome research, biotech for pets and more  WASHINGTON – (Feb. 23,…
The Creating Hope Reauthorization Act of 2024 was introduced in the House of Representatives this week. BIO CEO and President, Rachel King, made the following statement following the bill's introduction: "BIO strongly supports the House…
Legislation to restore immediate R&D expensing passed the House by 357-70 yesterday. Following the vote, BIO's Chief Advocacy Officer, Nick Shipley, made the following statement:  "The bipartisan legislation passed by the U.S. House…